Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-05-13
2003-06-10
Reamer, James H (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S034000, C514S326000, C514S353000, C514S338000, C514S416000, C514S419000, C514S254010, C514S015800
Reexamination Certificate
active
06576638
ABSTRACT:
FIELD OF INVENTION
The present invention refers to, the use of substance P antagonists particularly the invention refers to the use of NK-1 receptor antagonists for the treatment of adenocarcinomas, more particularly genito-urinary-tract neoplasms, more particularly prostatic carcinoma.
STATE OF THE ART
Malignant neoplasms, originating from epithelial cells are named carcinomas. A peculiar type of carcinoma, of glandular origin, is the adenocarcinomas. Since a correlation between tumors and angiogenesis has been hypothesized, a possible, effective strategy against cancer disease is a pharmacological treatment with angiogenesis inhibitors.
Angiogenesis, i.e. the formation and development of new capillary vessels, occurs in different physiologic conditions, such as embryonal development. On the other hand, intense angiogenesis occurs in several pathologic conditions, such as synovial rheumatoid hypertrophy, atherosclerosis, proliferative retinopathy and solid tumors. With reference to solid tumors, the interest in the neovascularisation has been raised from the evidence that tumors cannot growth or metastasize without new vessels and/or growth factors. Solid tumors cannot grow beyond 1-2 mm
3
without neovascularation, which furnishes feeding to tumors. Therefore, experiments have been carried out in order to quantify neovascularation in order to try to evaluate the tumor growth at different stages [Tosan A., Fregene et al, Anticancer Research 13: 2377-2382 (1993); 13: Brigitte V. Offersen et al., APMIS 106: 463-469 (1998)]. Consequently, it has been hypothesized that tumor growth could be prevented by neovascularization blockage.
Experimental evidences have recently outlined that substance P (SP) plays a role in angiogenesis stimulation:
Daily administration of substance P causes intense neovascularization in a rat sponge model of angiogenesis [T.-P. D. Fan et al, Br. J. Pharmacol. 110: 43-49 (1993)];
The angiogenic response towards SP can be blocked by using selective antagonists for NK-1 receptors for tachykinines [T.-P. D. Fan et al, Br. J. Pharmacol. 110: 43-49 (1993)];
The angiogenic activity of SP can be counteracted by administration of either peptide or non peptide antagonists [D. Regoli et al., Pharmacol. Rev., Vol. 64, No. 4 551-559 (1994)].
EP 0835662 describes peptide antagonists of substance P which are characterized by negative side effects. Henning Ivo M. et al., Int. J. Cancer. 61, 786-792 (1995) describes binding experiments for substance P receptors and hypothesizes that the progression of tumor is mediated via angiogenetic mechanisms.
Such experimental results have not yet led to identify any drug which could be successfully employed in the treatment of the adenocarcinomas, particularly the prostatic carcinoma. As a matter of fact, Fan et al. states about future therapeutic applications in the above mentioned mechanism.
Moreover, NK-1 antagonists show a great variability in their molecular structure (Regoli et al, 1994), therefore being very difficult to predict potential activity based upon their structure-activity relationship. Also, insofar, no data have currently shown that the antagonistic activity and selectivity towards the human subtype NK-1 receptor could be of interest in the therapy of adenocarcinoma, particularly of the prostatic adenocarcinoma. In relation to the current state of the art regarding cancer therapy, none of the tested substances seems to be effective in cancer therapy. Therefore for the substances mentioned in Regoli it cannot be inferred any specific activity against cancer.
With the present invention, we aim at inhibiting, via administration of inhibitors of angiogenesis and particularly by using of antagonists of NK-1 tachykinergic receptor, solid tumor growth specifically localized to the genito-urinary tract. This innovative methodology either substitutes or integrates current therapies against cancer, such as surgery, chemiotherapy and radiotherapy.
SUMMARY OF THE INVENTION
It is an object of the present invention the use of NK-1 receptor antagonists in the treatment of the adenocarcinomas, particularly in the treatment of the carcinomas of the genito-urinary tract and more particularly in the treatment of the prostatic adenocarcinoma.
Another object of the invention is the use of substance P antagonists in the treatment of the adenocarcinomas, particularly in the treatment of the carcinomas of the genito-urinary tract and more particularly in the treatment of the prostatic adenocarcinoma.
REFERENCES:
patent: 5716979 (1998-02-01), Horwell et al.
patent: EP 0 659 409 (1995-06-01), None
patent: EP 0 773 026 (1997-05-01), None
patent: EP 0 835 662 (1998-04-01), None
Hennig, I. M. et al.,Substance-P receptors in human primary neoplasms: Tumoral and vascular localization, Intl. Journ. of Cancer,vol. 61, pp. 786-792, 1995.
Kucharczyk, N.,Tachykinin Antagonists in Development, Expert Opinion on Investigational Drugs,vol. 4, No. 4, pp. 299-311, 1995.
M.A. Cascieri et al.Characterization of the Binding of a Potent, Selective, Radioiodinated Antagonist to the Human Neurokin-1 Receptor.Molecular Pharmacology vol. 42, pp. 458-463.
R. Cirillo et al.Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1receptor antagonist.European Journal Of Pharmacology vol.341, pp. 201-209 (1998).
M.C. Desai et al.Discovery of a Potent Substance P Antagonist: Recognition of the Key Molecular Determinant.J. Med. Chem vol. 35, pp. 4911-4913 (1992).
X. Emonds-Alt et al.In vitro and in vivo biological actitivies of SR140333, a novel potent non-peptide tachykinin NK1receptor antagonist.European Journal Of Pharmacology vol. 250, pp. 403-413 (1993).
S. Evangelista et al.Colitis Induced by Acetic Acid In Guinea-Pigs: Effect Of Men 11467, A Selective Pseudopeptide Tachykinin NK-1 Antagonist.Pharmacological Research—XXIX National Congress of Italian Pharmacological Society, Florence-Italy Jun. 20-23, 1999 Abstract Book, p. 90 (1999).
T.P. D. Fan et al.Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition by NK1or interleukin-1 receptor antagonists.Br. J. Pharmacol. vol. 110, pp. 43-49 (1993).
T. A. Fregene et al.Tumor—Associated Angiogenesis in Prostate Cancer.Anticancer Research vol. 13, pp. 2377-2382 (1993).
T. Fujii et al.Pharmacological profile of a high affinity dipeptide NK1receptor antagonist, FK888Br. J. Pharmacol. vol. 107, pp. 785-789 (1992).
C. J. Gardner et al.GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity.Regulatory Peptides vol. 65, pp. 45-53 (1996).
C. Garret et al.Pharmacological properties of a potent and selective nonpeptide substance antagonist.Proc. Natl. Acad. Sci. USA vol. 88, pp. 10208-10212 (Nov. 1991).
I. M. Hennig et al.Substance-P Receptors In Human Primary Neoplasms: Tumoral and Vascular Localization.Int. J. Cancer vol. 61, pp. 786-792 (1995).
B. V. Offersen et al.Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer.APMIS vol. 106, pp. 463-469 (1998).
D. Regoli et al.Receptors and Antagonists for Substance P and Related Peptides.Pharmacological Reviews vol. 46, No. 4, pp. 551-559 (1994).
W. Schilling et al.Approaches towards the Design and Synthesis of Nonpeptidic Substance-P Antagonists.pp. 207-220.
R. M. Snider et al.A Potent Nonpeptide Antagonist of the Substance P(NK1)Receptor.Science vol. 251, pp. 435-437 (Jan. 1991).
Massi Maurizio
Nabissi Massimo
Pompei Pierluigi
Sparapani Pier Luigi
Biopolis S.p.A.
Morgan & Finnegan L.L.P.
Reamer James H
LandOfFree
Use of substance P antagonists in the treatment of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of substance P antagonists in the treatment of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of substance P antagonists in the treatment of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3124639